Ovoca Bio PLC
OVB
Company Profile
Business description
Ovoca Bio PLC is a life science investment company. The company is engaged in investing in the development and commercialization of novel product candidates for the treatment of female sexual dysfunctions. The group has two business segments, bio-pharmaceutical and investment, which are operated principally in Russian Federation and investment activities operated from Bermuda, and with administrative activities in the Republic of Ireland. Its product candidate includes IVIX - Libicore - a novel synthetic peptide, administrated through a nasal spray.
Contact
17 Pembroke Street Upper
DublinD02 AT22
IRLT: +353 16619819
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
5
Stocks News & Analysis
stocks
What next for Tesla as 2024 deliveries disappoint?
Tesla shares started the year on a sour note. We think they continue to price in ambitious growth going forward.
stocks
Best and worst performing ASX sectors of 2024
Exploring the ASX sectors that moved the market this year.
stocks
2 ASX companies with the traits of a long-term winner
Two companies that show promising signs of handsomely rewarding shareholders.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,511.90 | 46.90 | 0.55% |
| CAC 40 | 7,282.22 | 111.54 | -1.51% |
| DAX 40 | 19,906.08 | 118.58 | -0.59% |
| Dow JONES (US) | 42,732.13 | 339.86 | 0.80% |
| FTSE 100 | 8,223.98 | 36.11 | -0.44% |
| HKSE | 19,760.27 | 136.95 | 0.70% |
| NASDAQ | 19,621.68 | 340.88 | 1.77% |
| Nikkei 225 | 39,894.54 | 386.62 | -0.96% |
| NZX 50 Index | 13,067.83 | 42.91 | -0.33% |
| S&P 500 | 5,942.47 | 73.92 | 1.26% |
| S&P/ASX 200 | 8,250.50 | 49.30 | 0.60% |
| SSE Composite Index | 3,211.43 | 51.13 | -1.57% |